Literature DB >> 7465607

Ketamine: convulsant or anti-convulsant?

M S Myslobodsky, V Golovchinsky, M Mintz.   

Abstract

Ketamine hydrochloride in doses producing narcotic-cataleptic effects (50--100 mg/kg, IP) reduced the intensity of picrotoxin convulsions and eliminated seizures caused by metrazol administration. Subcataleptic doses (5--20 mg/kg) increased the duration of mitigated convulsive symptoms (abortive grand mal fits, jerks) especially those evoked by picrotoxin. Narcotic-cateleptic doses of ketamine considerably increased the duration of the period of single and multiple jerks produced by picrotoxin administration. Both convulsants transformed 1--2 Hz "ketamine complexes" into 2--4 Hz Wave spike discharges which appeared in a quasi-periodic fashion alternating with periods of relatively suppressed electrocortical activity. Electroencephalographic grand mal patterns were typically dissociated from behavioral manifestations under 50--100 mg/kg of ketamine, followed by a short period of postictal depression and a rapid recovery of preseizure electrographic patterns. Findings suggest that mechanisms involved in seizure alleviation may be responsible for sustaining mitigated convulsive phenomena. Neuro-chemical processes underlying antiepileptic ketamine potency remain unknown.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7465607     DOI: 10.1016/0091-3057(81)90099-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  The time-frequency structure of the spike-wave discharges in genetic absence epilepsy.

Authors:  A V Gabova; D Yu Bosnyakova; M S Bosnyakov; A B Shatskova; G D Kuznetsova
Journal:  Dokl Biol Sci       Date:  2004 May-Jun

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex.

Authors:  P L Wood; T S Rao; S Iyengar; T Lanthorn; J Monahan; A Cordi; E Sun; M Vazquez; N Gray; P Contreras
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

4.  Antagonism of various tonic convulsions in mice by dextrorphan and dizocilpine.

Authors:  N Akaike; N Himori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

5.  Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.

Authors:  W Löscher; P Wlaź; C Rundfeldt; H Baran; D Hönack
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

7.  Different capability of N-methyl-D-aspartate antagonists to elicit EEG and behavioural phencyclidine-like effects in rats.

Authors:  S Sagratella; A Pezzola; P Popoli; A S Scotti de Carolis
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Methodological standards and interpretation of video-electroencephalography in adult control rodents. A TASK1-WG1 report of the AES/ILAE Translational Task Force of the ILAE.

Authors:  Shilpa D Kadam; Raimondo D'Ambrosio; Venceslas Duveau; Corinne Roucard; Norberto Garcia-Cairasco; Akio Ikeda; Marco de Curtis; Aristea S Galanopoulou; Kevin M Kelly
Journal:  Epilepsia       Date:  2017-11       Impact factor: 5.864

Review 9.  Ketamine: an update on the first twenty-five years of clinical experience.

Authors:  D L Reich; G Silvay
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

Review 10.  Comparison of anaesthetic- and seizure-induced states of unconsciousness: a narrative review.

Authors:  Benjamin F Gruenbaum
Journal:  Br J Anaesth       Date:  2020-09-18       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.